GALS identifies the most innovative, driven, and exciting companies to participate in the GALS program. Based on each company’s goals and needs, we offer individualized support in various areas, including strategic guidance, operational support, and access to our global network of experts and resources, to integrate companies into the U.S. life science ecosystem.
Adhesys Medical is a medical device company dedicated to developing innovative polyurethane-based surgical sealants. Their unique sealant technology, combining ease of use, flexibility, biodegradability, and wet space usability, has been in development since 2007.
In 2013, the company was founded in Aachen, Germany to commercialize the sealant technology, and expanded to Houston, Texas in 2015.
Adhesys’ vision is to bring their disruptive innovations to medical professionals everywhere to save lives, and improve medical outcomes and patient comfort.
Emperra revolutionizes Diabetes mellitus patient care. Its connected health solution uses a Bluetooth-enabled insulin pen and proprietary software to provide real-time factual analytics that allows caregivers to focus on patients with medical needs while empowering patients to take charge of their diabetes.
InGeneron was formed to innovate cell-based technologies for healthcare, veterinary and life science research. InGeneron’s advanced cell separation technologies enable preparation of adipose-derived regenerative cells, including stem cells, that have the potential to aid physicians and veterinarians in the treatment of a number of diseases, orthopedic injuries and cosmetic procedures. InGeneron is a privately held company, developing its own products for multiple markets and expanding its reach through licensing agreements. Its research and development capability spans the disciplines of biomedical engineering, cellular as well as molecular biology, and pharmacology.
PEPperPRINT, headquartered in Heidelberg, Germany has developed a novel technology to directly print 3D peptide libraries by coupling individual amino acids in situ to form linear peptide chains. The advantage of this technology is its unlimited diversity of peptide sequences that can be synthesized in parallel, using only very small quantities at low cost. Any peptide content can be customized in array format at high spot density. Applications are in antigen and biomarker discovery, high-resolution linear and cyclic epitope mapping, serum antibody profiling, vaccine and peptide drug development, as well as peptide target binder identification and optimization. PEPperPRINT also produces preprinted arrays for cancer and autoimmune and infectious diseases (e.g., Dengue, Zika, EBV).
Rigontec is a leader in RIG-I targeting therapeutics. Utilizing its proprietary RIG-I agonist platform, Rigontec harnesses one of the most essential pathways in the innate immune system to pioneer a novel immuno-oncology treatment approach for immediate and long-term anti-tumor immunity.
Personal MedSystems develops mobile and innovative ECG technologies that allow both patients and physicians to perform instant heart checks wherever they are. Its product CardioSecur is the first and only mobile 22-lead ECG system with only 4 electrodes. Personal MedSystems has locations in Berlin and Frankfurt, Germany.
AYOXXA Biosystems has invented a technology platform to analyze very low amounts of multiple protein biomarkers in biological samples, simultaneously and with high precision. Its LUNARIS™ BioChips technology innovates proteome research in biomedicine, pharmacological screening, and preclinical diagnostics development. Core to its technology is a bead-based method that yields 10,000-fold more data points than a standard immunoassay. AYOXXA Biosystems GmbH is based in Cologne (Germany), Singapore, and now Cambridge, Massachusetts.
Sonormed is a medical technology company with a focus on digital audiology. Its interdisciplinary team of sound engineers, computer scientists, and neurobiologists develop and distribute the certified medical product Tinnitracks. Tinnitracks is a neuro-acoustic treatment option for tinnitus patients, available as a smartphone and web app. It targets a patient’s individual tinnitus frequency via sophisticated filtering algorithms applied to his/her favorite music.
GALS has established mentor relationships with experts in medical devices and business development. GALS facilitates connections to accomplished FDA regulatory experts and consults on marketing strategy specific to the U.S. healthcare market. GALS also provides advice on fundraising in the U.S. and helps set up meetings with potential investors.
Artikel: “Wir entziehen dem Tumor die Tarnung”
Neues Verfahren von Rigontec in der Immunoonkologie
Adhesys Medical acquired by Grünenthal Group
April 7, 2017
The Grünenthal Group today announced the acquisition of the company Adhesys Medical to expand its pipeline of medical devices for its business with surgeons The acquisition of Adhesys Medical and its highly innovative pipeline of surgical sealants, together with the underlying technology platform, allows Grünenthal to tap into the global $1 billion surgical sealants market
The Berlin Institute of Health adopts labfolder’s digital lab data management platform
April 6, 2017
The Berlin Institute of Health (BIH) adopts the digital laboratory data management platform from the Berlin-based start-up labfolder
Press Release: Adhesys Medical Announces Collaboration with GALS
March 14, 2017
Adhesys Medical, a medical device company developing the next generation of surgical adhesives, announced today its acceptance into the German Accelerator Life Sciences (GALS) program.
InGeneron Completes Strategic Financing from Sanford Health to Advance Regenerative Cell Therapies
March 6, 2017
InGeneron Inc. announced that Sanford Health, one of the largest integrated healthcare providers in the U.S., has invested $20 million in the company in the form of a Series D financing.
Scopis Receives FDA 510(K) and Health Canada MDL Clearance
February 28, 2017
Scopis announced that it has received 510(K) clearance from the U.S. Food and Drug Administration and Health Canada Medical Device License for its breakthrough next-generation surgical navigation products for ENT surgery.
Scopis Initiates Collaboration with the German Accelerator Life Sciences
January 23, 2017
Scopis, a tech company specializing in surgical navigation and medical augmented reality, announced today its collaboration with the German Accelerator Life Sciences (GALS) program.
Personal MedSystems GmbH gains international consortium and closes series B financing.
January 17, 2017
Personal MedSystems GmbH has closed their Series B financing with a volume of 5 million EUR. A further 0.7 million EUR from existing investors is expected. The capital will be used for sales growth and continued innovation on its technology and data platform.
InGeneron Initiates Collaboration with German Accelerator Life Sciences
December 5, 2016
InGeneron, a regenerative medicine and biotechnology company, today announced its acceptance to the German Accelerator Life Sciences (GALS) program. InGeneron will be establishing an additional U.S. presence in Cambridge, MA.
InGeneron Presents Results from Investigator Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS
November 21, 2016
InGeneron, Inc. announced today the presentation of initial data from an investigator initiated case series using its proprietary adipose-derived regenerative cell (ADRC) technology for the treatment of facet joint syndrome, one of the major causes of chronic back pain.
PEPperPRINT: Hit Validation and Affinity Determination Service
November 17, 2016
PEPperPRINT offers the confirmation and affinity determination of primary hit peptides to a target protein or antibody in a soluble, homogenous format using fluorescence polarization as quantitative measure for protein-peptide binding.
Rigontec Appoints Dr. Jörg Vollmer as Chief Scientific Officer
November 15, 2016
Rigontec announced today that Dr. Jörg Vollmer has joined the Company as Chief Scientific Officer. Dr. Vollmer brings to Rigontec more than 17 years of drug discovery and development experience
Scopis introduces TGS®-Target Guided Surgery ENT Navigation to the US market
November 2, 2016
Scopis introduced their TGS® - Target Guided Surgery navigation system to the large number of delegates in attendance at the 120th AAO-HSNF Annual Meeting. Delegates had the opportunity to use Scopis Building Blocks® planning software that incorporated the new International Frontal Sinus Anatomy Classification (IFAC).
Rigontec Raises Additional €15M in Extended Series A to Advance Novel RIG-I Targeted Immuno-Oncology Therapeutics
September 6, 2016
Rigontec announced that it secured EUR 15 million in a third and final closing of its Series A round. The funding will advance the ongoing development of Rigontec’s RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as accelerate the progress of lead candidate RGT100 towards the clinic.
Scopis is a Finalist at the German Founders’ Award 2016
May 23, 2016
Scopis is one of the last three competitors for the German Founders’ Award 2016 in the Climber category.
PEPperPRINT Product Update: PEPperCHIP® Autoimmune Epitope Microarray 3.0 released
May 18, 2016
The new PEPperCHIP® Autoimmune Epitope Microarray 3.0 covers 4,287 linear autoimmune epitopes including 286 citrullinated peptides as well as the corresponding arginine variants.
Scopis GmbH awarded the Fraunhofer Start-up Prize
February 23, 2016
The Fraunhofer Start-up Prize recognizes the current success and phenomenal development of the Fraunhofer spin-off on the international market for medical technology.
Biotech Showcase™ 2016: Interview: Rigontec details immuno-oncology strategy
February 3, 2016
Rigontec GmbH CEO Dr. Christian Schetter explains to Mike Ward, Informa Pharma Insights global director of content, how his company is developing a new class of RNA-based immunotherapeutics to treat cancers and viral diseases by targeting RIG-I.
First Four Companies Selected to Participate in the German Accelerator Life Sciences Program in Cambridge
January 13, 2016
During the 34th JP Morgan Healthcare Conference, the German Accelerator Life Sciences (GALS) announced the first four companies to participate in its Cambridge-based program. AYOXXA Biosystems, PEPperPRINT, Personal MedSystems, and Sonormed will receive support tailored towards the specific needs of each company.
Sonormed’s innovative Tinnitus-treating app wins award at SXSW
March 19, 2015
A soon-to-be-released app for treating tinnitus turned heads at the South-by-Southwest Music, Film and Interactive Festival (SXSW) in Austin, Texas for its innovative approach to treatment. With Tinnitracks, treating tinnitus is as simple as listening to your favorite music for at least one hour per day for six months in a quiet surrounding.